Introduction: A Brief History of the Adult Mammalian Neurogenesis Discovery
===========================================================================

The discovery of adult neurogenesis crushed the century-old dogma that no new neurons are formed in the mammalian brain after birth. However, this finding and its acceptance by the scientific community did not happen without hurdles. At the beginning of the last century, based on detailed observations of the brain anatomy reported by Santiago Ramon y Cajal and others, it was established that the human nervous system develops *in utero* (Colucci-D\'Amato et al., [@B16]). In adult brains, it was thought, no more neurons could be generated, as the brain is grossly incapable of regenerating after damage (for a more detailed historical report see Watts et al., [@B161]; Whitman and Greer, [@B164]). This dogma was deeply entrenched in the Neuroscience community, and Altman\'s ([@B1]) discovery of newborn cells in well-defined areas of the adult rodent brain was largely ignored. The phenomenon was reexamined in the 1970--1980s, when Michael Kaplan (Kaplan and Hinds, [@B68]) and Fernando Nottebohm (Goldman and Nottebohm, [@B45]) demonstrated the presence of newborn cells in the adult brain of mice and canaries, respectively, and showed that these cells had ultrastructural characteristics of neurons. However, such findings could not be repeated in adult rhesus monkeys, where proliferating cells appeared to be glial and endothelial cells and not neurons (Rakic, [@B121]; Eckenhoff and Rakic, [@B37]). Thus, neurogenesis seemed to be absent in adult primates (Eckenhoff and Rakic, [@B37]).

The field of adult neurogenesis finally took off in the 1990s with the development of new technologies. First, the use of ^3^H-thymidine, a radioactive nucleotide used to study proliferation when incorporated into the cells during the S phase of the cell cycle, was replaced by its analog, bromodeoxyuridine (BrdU), which could be detected by a specific antibody. Utilization of the BrdU for labeling of newborn cells via immunohistochemistry allowed their further studies by co-labeling with specific neuronal markers (Miller and Nowakowski, [@B102]). Further, it was shown that neuroprogenitor cells (NPCs), isolated from adult mouse brains, proliferated and differentiated into neurons and astrocytes *in vitro* (Reynolds and Weiss, [@B127]). In addition, NPCs labeled with viral vectors were able to migrate and differentiate into neurons in the adult mouse brain (Lois and Alvarez-Buylla, [@B87]), demonstrating that the adult neurogenesis was functional in rodents. Finally, the existence of adult neurogenesis in humans was firmly established when, in 1998, Gage and colleagues demonstrated for the first time that new neurons were produced in the adult hippocampus (Eriksson et al., [@B39]).

Currently, adult neurogenesis is one of the hot topics in Neuroscience especially because of the new opportunities it may bring for treatments of neurodegenerative diseases, either by harnessing resident progenitors to regenerate the lost tissue (Sohur et al., [@B145]) or by cell transplantation therapies (Goldman and Windrem, [@B46]). The field is currently on the rise, as shown by the exponential growth of publications with the key words "adult" AND "neurogenesis OR neural stem cells" (PubMed search up to December 31, 2010): a total of 6,437 papers have been published, of which 57% (3,695 papers) was published in the last 5 years (Figure [1](#F1){ref-type="fig"}). However, only 8% of published papers (530 papers) deal with human data (search including the term "human" in the title), suggesting that the research on adult neurogenesis in humans is still in its infancy. Thus, the actual knowledge on adult human neurogenesis is limited and in many cases, data is directly extrapolated from the rodent literature. Herein, we review the methodologies used to assess adult human neurogenesis and its status in several neuropsychiatric disorders.

![**Published papers on adult neurogenesis per quinquennium**. The graph shows the accumulated papers published from 1960 onward, searched in PubMed with the search terms "adult" AND ("neurogenesis" OR "stem cells"). The asterisks show the total number of papers, and the filled squares show those papers with the term "human" in their title.](fnins-05-00047-g001){#F1}

Methods to Assess Neurogenesis in Humans
========================================

The extent of our knowledge on adult human neurogenesis directly correlates with the type of available techniques that can be applied to human brain tissue research. Several methodologies exist, but each method yields different sensitivity, specificity, and ultimately different units of quantification, thus rendering it difficult to compare different studies. In addition, some methodologies can assess only proliferation (NPCs or total proliferating cells) while others can provide the data on neurogenesis \[neuroblasts (NBs, neuronal committed cells) or newborn neurons\]. Herein, we review the advantages and disadvantages of methods used to assess adult human neurogenesis both *ex vivo* and *in vivo*.

Methods to assess neurogenesis on postmortem and biopsied tissue
----------------------------------------------------------------

The majority of the methodologies used to study neurogenesis *ex vivo* have been inherited from the rodent literature, where they have been thoroughly validated (Figure [2](#F2){ref-type="fig"}). These techniques require brain tissue that is obtained postmortem, either frozen fresh immediately after death or, more frequently, fixed and stored in brain tissue banks. In both cases, it is important to note that the cause of death, presence of brain and/or systemic illnesses, age of death, and postmortem interval (the time from death to tissue fixation) may be confounding factors when interpreting the results (Boldrini et al., [@B13]). Alternatively, brain tissue can also be obtained from biopsies or surgical resections, such as in temporal lobectomy due to intractable epilepsy.

![**Methods to assess adult human neurogenesis in resected or postmortem brain samples**. Brain samples from live individuals can be obtained by surgical resection of the focus of the seizures in intractable epilepsy or brain tumors. Alternatively, bank tissues store frozen or fixed brain samples from accidental deaths and aging individuals, some of which may have been treated with BrdU. Once the tissue is obtained, three main methods can be applied to study neurogenesis: **(A)** Immunodetection of BrdU and/or proliferation and cell-type specific biomarkers in fixed tissue, followed by analysis by confocal analysis. An example of new born neurons in the SGZ of the hippocampus of an aging patient is shown in **(A1)** NeuN+ neurons (red), **(A2)** BrdU labeling (green), **(A3)** GFAP+ astrocytes (blue), **(A4)** merged image showing one newborn neuron labeled with BrdU and NeuN, but not with GFAP (arrow); and non-specific fluorescence emission due to lipofuscin accumulation in old tissue (arrowhead). Scale bar is 25 μm. **(B)** Culture of NPCs. In this case, the fresh tissue is dissociated and transfected with a reporter gene (GFP) driven by a Tα1 tubulin promoter, an early neuronal regulatory gene. The transfected cells are then purified by FACS and cultured *in vitro*. The grown cells differentiate into fully functional neurons which when patch-clamped in a voltage-clamped configuration **(B1)** show typical depolarizations of the voltage-gated sodium currents measured in nanoAmperes (nA) over a time course of milliseconds (ms) **(B2)**. **(C)** Determination of the ^14^C content. Cell nuclei from prefrontal cortex samples are purified by density gradients, labeled with NeuN and purified by FACS. Next, their DNA is purified and the ^14^C content is analyzed by mass spectrometry. **(C1)** FACS plot showing the expression of NeuN (vertical axis) versus the area of the forward scatter (FSC-A, which is considered a measure of the particle size). The neuronal nuclei (NeuN+, orange) are separated from the rest of the nuclei (NeuN−, green). **(C2)** ^14^C content of the sorted nuclei (Δ^14^C, given in relation to a universal standard and corrected for radioactive decay) compared to the atmosphere ^14^C content (blue line) and the age of the individual (vertical black line). Neuronal nuclei (orange triangles) have a ^14^C content that indicates that their age is coincident with that of the individual. Non-neuronal nuclei (green circles) are younger than the individual, making the non-sorted (black squares) cells younger than the individual in average as well. Figures **(A1--A4)** and **(B1--B2)** are reprinted by permission from Macmillan Publishers Ltd: Nature Medicine, Eriksson et al. ([@B39]), copyright 1998; and Roy et al. ([@B131]), copyright 2000, respectively. Figures **(C1--C2)** are reprinted by permission from Bhardwaj et al. ([@B10]), copyright 2006, National Academy of Sciences, U.S.A.](fnins-05-00047-g002){#F2}

### Bromodeoxyuridine labeling

Bromodeoxyuridine is widely used in animal models to quantify the number of dividing cells in a tissue and to trace their progeny. When administered systemically, it is incorporated into the DNA during the S phase of the cell cycle and is transmitted to the daughter cells, as long as it is not diluted through many rounds of proliferation (Karpowicz et al., [@B69]). Using a variety of specific anti-BrdU antibodies, it can be detected by immunohistochemistry. Although it can be mutagenic (Rakic, [@B122]), BrdU was approved in 1995 by the Food and Drug Administration (FDA) to be used in humans under the commercial name of Broxine/Neomark as a radiation sensitizer in the treatment of primary brain tumors[^1^](#fn1){ref-type="fn"}. Furthermore, BrdU is currently used in several clinical trials to measure cell cycle kinetics in patients with hematologic malignancies, to study white blood cell replication and survival in patients with human immunodeficiency virus, and to assess the degree of tumor proliferation in biopsies as well as to treat patients with pancreatic tumors as an antineoplastic agent[^2^](#fn2){ref-type="fn"}. It was the treatment with BrdU of patients who suffered from larynx, pharynx, or tongue cancers that enabled the detection of proliferating NPCs in the hippocampus (Eriksson et al., [@B39]), the discovery which paved the way for further investigations of adult neurogenesis in the human brain.

The major advantage of BrdU labeling is its sensitivity to detect proliferating cells compared to other immunohistological methods. For instance, neurogenesis in adult rhesus monkeys was only detected using BrdU (Kornack and Rakic, [@B74]) but not H^3^-thymidine, which also incorporates into the DNA of dividing cells (Rakic and Nowakowski, [@B124]). In addition, proliferation in the adult human hippocampus was found using BrdU (Eriksson et al., [@B39]), but not other markers of proliferation such as MiB-1 (Seress et al., [@B138]). Another advantage of BrdU labeling is utilization of pulse-and-chase analysis, which enables studies of both proliferation (hours after the BrdU injection) and differentiation (days or months after the BrdU injection). Such studies may ultimately be used to distinguish between neurogenesis and gliogenesis, a particularly significant feature in human brain diseases.

Despite its wide use, BrdU labeling has some drawbacks. For instance, BrdU does not diffuse freely through the blood--brain barrier (BBB), but rather, it likely uses the deoxythymidine transporters (Spector and Johanson, [@B147]). Therefore, conditions that disrupt the BBB, such as inflammation, irradiation, status epilepticus, trauma, etc., may lead to different BrdU availability which, in turn, leads to labeling of different number of cells without actual changes in proliferation (von Bohlen Und Halbach, [@B160]). To overcome this possible cause of misinterpretation of the data, it is particularly important to determine the integrity of the BBB when comparing neurogenesis in healthy and diseased individuals. Furthermore, BrdU can label phenomena other than proliferation, such as DNA turnover or repair, or abortive reentry in the cell cycle during apoptosis (Rakic, [@B122],[@B123]). Finally, some dividing cells may preferentially use *de novo* synthesis of deoxythymidine rather than the salvage enzymes which phosphorylate existing deoxynucleotides (including BrdU) to generate the deoxynucleotides for DNA synthesis during the S phase (Spector and Johanson, [@B147]). In such cases, BrdU labeling will not correlate with the proliferative activity of the cells. Thus, while it has revolutionized the studies of neurogenesis, BrdU labeling should be meticulously analyzed to avoid possible misinterpretations as noted above.

### Expression of cell-specific biomarkers

Particular cell types and particular stages of the cell cycle of dividing cells can be assessed by specific antibodies. When utilizing these reagents for immunostaining of the human tissue, it is important to take into account antigenicity, which can be affected by the delayed fixation of the postmortem tissue (Boekhoorn et al., [@B12]; Liu et al., [@B85]) and the specificity of the antibodies, which may be related to a particular species (for example, antibodies which work for rodent tissue may not work for human tissue). Ideally, quantification of cells expressing the biomarker of interest should be obtained using unbiased stereology, such as the optical dissector method (Lemmens et al., [@B79]), although in human samples this goal can be difficult to achieve due to the low number of proliferating cells (Liu et al., [@B85]).

*Proliferation biomarkers* are expressed while cells are cycling (Table [1](#T1){ref-type="table"}), such as *Ki-67* (Hall and Woods, [@B51]; Yerushalmi et al., [@B167]) and *MCM2* (Stoeber et al., [@B149]; Bailis and Forsburg, [@B7]). Ki-67 immunolabeling relies heavily on pH (Boekhoorn et al., [@B12]); thus other antibodies against the Ki67 antigen, such as *MIB-1*, have been developed for different tissue conditions (Cattoretti et al., [@B14]). Another widely used marker is *PCNA* (Takasaki et al., [@B151]), although it is also expressed by some non-proliferating cells (Rakic, [@B122]). Compared to BrdU, these markers offer the advantage of not requiring a priori administration of the label, thus increasing the number of samples that can be studied. However, these markers only label proliferating cells and cannot be used to trace their fate or to assess actual neurogenesis. Importantly, proliferation biomarkers in neurogenic regions are usually assumed to label NPCs, but it is also possible that they label proliferating astrocytes, oligoprogenitors, or endothelial cells. Gliogenesis should be ruled out by double-labeling with specific glial biomarkers.

###### 

**Proliferation and cell-type specific biomarkers commonly used in human neurogenesis studies**.

  Antigen                        Function                                                                                                    Expression                                         References
  ------------------------------ ----------------------------------------------------------------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PROLIFERATION BIOMARKERS**                                                                                                                                                                  
  Ki67                           Unknown                                                                                                     Expression during G1-M                             Del Bigio ([@B25]), Blumcke et al. ([@B11]), Bedard and Parent, ([@B8]), Sanai et al. ([@B134]), Boekhoorn et al. ([@B12]), Jin et al. ([@B64]), Macas et al. ([@B93]), Reif et al. ([@B126]), Ziabreva et al. ([@B175]), Fahrner et al. ([@B40]), Shen et al. ([@B141]), Boldrini et al. ([@B13]), Mattiesen et al. ([@B99]), Knoth et al. ([@B72]), Marti-Fabregas et al. ([@B98])
  PCNA                           Proliferating cell nuclear antigen, a co-factor of DNA-PolΔ                                                 Synthesized during S phase                         Bernier et al. ([@B9]), Curtis et al. ([@B21], [@B22],[@B23]), Bedard and Parent ([@B8]), Hoglinger et al. ([@B55]), Crespel et al. ([@B18]), Jin et al. ([@B64]), Liu et al. ([@B85]), Shen et al. ([@B141]), Gerber et al. ([@B44]), Kam et al. ([@B67]), Mattiesen et al. ([@B99]), Knoth et al. ([@B72])
  MCM2                           Minichromosome maintenance protein 2, a DNA helicase                                                        Throughout cell cycle                              Jin et al. ([@B64]), Liu et al. ([@B85]), Shen et al. ([@B141]), Knoth et al. ([@B72])
  **CELL-SPECIFIC BIOMARKERS**                                                                                                                                                                  
  Nestin                         An intermediate filament                                                                                    NPC, astrocytes, radial glia, perivascular cells   Arnold and Trojanowski ([@B3]), Blumcke et al. ([@B11]), Bedard and Parent ([@B8]), Hoglinger et al. ([@B55]), Crespel et al. ([@B18]), Jin et al. ([@B64]), Macas et al. ([@B93]), Ziabreva et al. ([@B175]), Boldrini et al. ([@B13]), Mattiesen et al. ([@B99]), Knoth et al. ([@B72]), Marti-Fabregas et al. ([@B98])
  EGFR                           Epidermal growth factor receptor                                                                            C cells, A cells                                   Weickert et al. ([@B163]), Hoglinger et al. ([@B55])
  GFAP                           Glial fibrillary acidic protein, an intermediate filament                                                   Quiescent NPCs, B cells, radial glia, astrocytes   Eriksson et al. ([@B39]), Del Bigio ([@B25]), Bernier et al. ([@B9]), Weickert et al. ([@B163]), Blumcke et al. ([@B11]), Curtis et al. ([@B21]), Hoglinger et al. ([@B55]), Sanai et al. ([@B134]), Crespel et al. ([@B18]), Boekhoorn et al. ([@B12]), Macas et al. ([@B93]), Fahrner et al. ([@B40]), Shen et al. ([@B141]), Boldrini et al. ([@B13]), Gerber et al. ([@B44]), Kam et al. ([@B67]), Mattiesen et al. ([@B99]), Knoth et al. ([@B72]), Marti-Fabregas et al. ([@B98])
  Vimentin                       An intermediate filament                                                                                    Quiescent NPCs, B cells, astrocytes                Arnold and Trojanowski ([@B3]), Curtis et al. ([@B21], [@B22]), Crespel et al. ([@B18]), Fahrner et al. ([@B40]), Mattiesen et al. ([@B99])
  Musashi                        An RNA-binding protein                                                                                      NPC, astrocytes                                    Crespel et al. ([@B18]), Macas et al. ([@B93]), Ziabreva et al. ([@B175]), Shen et al. ([@B141]), Mattiesen et al. ([@B99])
  PSA-NCAM                       Polysialylated cell adhesion molecule, involved in cell migration                                           Migrating neuroblasts                              Mikkonen et al. ([@B101]), Bernier et al. ([@B9]), Weickert et al. ([@B163]), Bedard and Parent ([@B8]), Hoglinger et al. ([@B55]), Crespel et al. ([@B18]), Curtis et al. ([@B23]), Boekhoorn et al. ([@B12]), Macas et al. ([@B93]), Liu et al. ([@B85]), Kam et al. ([@B67]), Marti-Fabregas et al. ([@B98])
  DCX                            Doublecortin, promotes microtubule proliferation                                                            Neuroblasts and neurons                            Bedard and Parent ([@B8]), Crespel et al. ([@B18]), Boekhoorn et al. ([@B12]), Jin et al. ([@B64]), Fahrner et al. ([@B40]), Liu et al. ([@B85]), Shen et al. ([@B141]), Gerber et al. ([@B44])
  NeuroD                         A transcription factor, involved in neuronal commitment                                                     Neuroblasts and neurons                            Bedard and Parent ([@B8]), Knoth et al. ([@B72])
  TOAD64                         Turned on after division 64, a membrane associated protein from the TUC4 family involved in axonal growth   Neuroblasts                                        Jin et al. ([@B64]), Shen et al. ([@B141]), Gerber et al. ([@B44]), Mattiesen et al. ([@B99]), Knoth et al. ([@B72])
  NeuN                           A splicing factor of the Fox-3 family                                                                       Neurons                                            Eriksson et al. ([@B39]), Weickert et al. ([@B163]), Blumcke et al. ([@B11]), Curtis et al. ([@B21]), Crespel et al. ([@B18]), Fahrner et al. ([@B40]), Liu et al. ([@B85]), Boldrini et al. ([@B13]), Knoth et al. ([@B72]),
  βIII-Tubulin                   A microtubule                                                                                               Neurons                                            Arnold and Trojanowski ([@B3]), Bernier et al. ([@B9]), Weickert et al. ([@B163]), Blumcke et al. ([@B11]), Curtis et al. ([@B21], [@B23]), Bedard and Parent ([@B8]), Hoglinger et al. ([@B55]), Jin et al. ([@B64]), Macas et al. ([@B93]), Liu et al. ([@B85]), Shen et al. ([@B141]), Knoth et al. ([@B72])
  NSE                            Neuron specific enolase                                                                                     Neurons                                            Eriksson et al. ([@B39]), Del Bigio ([@B25])

*The function and expression of the different markers and the papers in which they were used are shown*.

*Cell-specific biomarkers* can also be detected using specific antibodies (thoroughly reviewed by von Bohlen Und Halbach, [@B160]; Encinas and Enikolopov, [@B38]). The most common cell biomarkers used for studies of the human tissue are described in Table [1](#T1){ref-type="table"}: *Nestin* (Lendahl et al., [@B80]), *GFAP* (Doetsch et al., [@B32]), *Vimentin* (Doetsch et al., [@B32]), *EGFR* (Danilov et al., [@B24]), *Musashi* (Sakakibara and Okano, [@B132]), *PSA-NCAM* (Doetsch et al., [@B32]), *Doublecortin* (DCX; des Portes et al., [@B27]), *NeuroD* (Miyata et al., [@B105]), *TOAD-64* (Minturn et al., [@B103]), *NeuN* (Mullen et al., [@B109]; Kim et al., [@B71]), NSE (Kaiser et al., [@B66]), and β*III-Tubulin* (Encinas and Enikolopov, [@B38]). However, caution must be observed when using these antibodies to assign the cell identity. For instance, apart from labeling migrating NBs, PSA-NCAM is also involved in synaptic plasticity (Dityatev et al., [@B29]) and is expressed in non-neurogenic areas in rodents (Nacher et al., [@B110]). In addition, the specificity of DCX as a marker for neurogenesis has been recently challenged, as it has been found in mature astrocytes in the human neocortex in patients suffering from neurodegeneration (Verwer et al., [@B158]). Finally, some authors (Boekhoorn et al., [@B12]), but not others (Liu et al., [@B85]), find that DCX immunolabeling is very sensitive to postmortem delay, an important confounding factor when comparing human postmortem samples.

### NPC culture

Human NPCs have been isolated and cultured *in vitro*. Originally, Steindler and colleagues were able to grow NPCs from the temporal lobe tissue extracted from patients with intractable epilepsy. These NPCs proliferated *in vitro* in the form of neurospheres and differentiated into neurons and astrocytes (Johansson et al., [@B65]; Kukekov et al., [@B76]). Later on, Goldman and colleagues refined the technique and were able to specifically isolate the NPCs (Roy et al., [@B131]). They transfected cells from mixed brain cultures with viral constructs expressing a humanized green fluorescent protein (GFP) under regulatory elements of the nestin or the early neuronal Tα1 tubulin genes, and then purified the NPCs based on the expression of the transgene by fluorescence-activated cell sorting (FACS). The isolated NPCs divided in culture and gave rise to physiologically active neurons (Roy et al., [@B131]). This technique was not designed for quantification purposes and, thus, cannot be used to assess the degree of neurogenesis in different disorders or after different treatments. Nonetheless, it has generated a great excitement because it was seen as the first serious step toward cell replacement therapies for human neurological diseases by transplantation of either precursors or already differentiated cells (Antel et al., [@B2]).

### ^14^C retrospective labeling

Similar to the ^14^C-dating used in archeology, this method uses the ^14^C-content to assess the average age of the cells present in a particular tissue (Spalding et al., [@B146]; Bhardwaj et al., [@B10]). Due to the extensive testing of nuclear weapons in the 1950--1960s, large quantities of ^14^C were generated; since then, the ^14^C levels in the biosphere have decayed at a known rate. This ^14^C incorporates into the cells, matching the ^14^C levels in the atmosphere. The exception is genomic DNA because the molecular composition of DNA is stable after the last cell division (except in case of DNA repair). The DNA ^14^C-content reflects the age of the cell and not the atmospheric levels (Spalding et al., [@B146]; Bhardwaj et al., [@B10]). Thus, the strategy devised by the Jonas Frisen\'s group was to isolate cell nuclei from fresh or frozen brain autopsy specimens and label them with NeuN. Next, neuronal nuclei (NeuN+) were sorted by FACS, their DNA purified and the ^14^C-content measured by accelerator mass spectrometry (Spalding et al., [@B146]; Bhardwaj et al., [@B10]). Using this technique, it was shown that neurogenesis in the adult neocortex is absent or very limited because the age of the neurons matched the age of the individual and had ^14^C levels similar to atmospheric levels at the time when the individual was born (Bhardwaj et al., [@B10]). On the contrary, NeuN-nuclei, including glial cells which are known to have a higher turnover rate, showed an average age several years younger than the age of the individual, suggesting that those were cells born during adulthood (Bhardwaj et al., [@B10]). This method yields high sensitivity as it has been estimated that it detects newborn cells down to 1% of the population (Bhardwaj et al., [@B10]). However, it only provides the average age of the neurons in the tissue and does not allow dating or tracing of individual cells. Surprisingly, this method has not yet been used to test adult neurogenesis in the hippocampus or the olfactory bulb (OB), the two major areas of adult neurogenesis.

Methods to assess neurogenesis *in vivo*
----------------------------------------

More recently, methods have been specifically designed to detect neurogenesis in live human brain by means of magnetic resonance imaging (MRI; Figure [3](#F3){ref-type="fig"}). In the MRI scanner, the subjects are exposed to a harmless magnetic field that aligns the magnetic spin of all the protons in the tissue in a low energy configuration; next, the subjects receive radiofrequency electrical stimulation, which excites the spins out of equilibrium. The spins then naturally relax back to their original conformation with time constants T1 (spin--lattice relaxation time, for longitudinal magnetization) and T2 (spin--spin relaxation time, for transversal magnetization; Maletic-Savatic et al., [@B95]). The difference in relaxation times of different molecules, such as water and fat, is used to generate detailed MRI images of the brain. In addition, further information can be extracted from these constants, and different MR modalities have been adapted to study neurogenesis (Modo and Bulte, [@B106]).

![**Live methods to assess adult human neurogenesis**. These methods are based on magnetic resonance, using MRI scanners available in hospitals worldwide. Because there are no side effects, both healthy and diseased people can be re-scanned throughout aging, before and after exercise, to follow-up the effect of pharmacological interventions, etc. Two main methods have been developed to indirectly quantify adult human neurogenesis using different MR modalities: **(A)** CBV measurement. The dentate gyrus CBV is a proxy for neurogenesis in physical exercise paradigms. This method is based on the consecutive correlation of neurogenesis--angiogenesis, and angiogenesis--CBV. **(A1)** High resolution MRI slice of the adult human hippocampus (right panel), showing the different hippocampal subregions (entorhinal cortex, EC, green; dentate gyrus, DG, red; cornu ammonis 1, CA1, light blue; and subiculum, SUB, yellow; central panel) and a typical hippocampal CBV map (warmer colors indicate higher CBV). **(A2)** Quantification of the mean relative hippocampal CBV (rCBV), before (white bars) and after (black bars) exercise in healthy humans. As in mice, physical exercise resulted in a significant increase in CVB only in the DG (asterisk). **(B)** Spectroscopy. A lipidic metabolite resonating at 1.28 ppm was identified as a marker of rodent NPCs. **(B1)** Positioning of the voxel of interest in the cortex and the hippocampus of a healthy person. **(B2)** Spectroscopic analysis of the metabolite content in the hippocampal voxel using SVD and FFT (small upper insert). Identified metabolites are myoInositol (mI, light blue), choline (Cho, purple), creatine (green), *N*-acetylaspartate (NAA, dark blue), and the 1.28 ppm metabolite (red). **(B3)** Quantification of the abundance of the 1.28 ppm metabolite in the cortical (CTX) and hippocampal voxels (LH and RH for left and right hippocampus, respectively), normalized over the amplitude of the creatine peak. The hippocampi had much higher content of the 1.28 ppm metabolite than the cortex. The MRI cutaway is printed from permission from the National High Magnetic Field Lab website (<http://www.magnet.fsu.edu/education/tutorials/magnetacademy/mri/>). Figures **(A1--A2)** are reprinted by permission from Pereira et al. ([@B119]), copyright 2007, National Academy of Sciences, U.S.A. Figures **(B1--B3)** are from Manganas et al. ([@B96]) and are reprinted with permission from AAAS.](fnins-05-00047-g003){#F3}

The major advantage of MR-based methods is that they are performed in live individuals with no side effects, supporting repeated measures and longitudinal studies. Thus, these methods allow a more controlled experimental design, and variables such as the cause or age of death no longer have to be taken into account. Nonetheless, these methods rely on correlations to indirectly quantify neurogenesis, and extensive validation in both rodents and humans is required to demonstrate that they are specific for neurogenesis. More importantly, it is essential to determine whether the data correlate with the number of NPCs, proliferating NPCs (versus other cell types that proliferate), or newborn neurons. Another major advantage of MRI-based methods is that MRI scanners are widely available in hospitals and research centers worldwide. Thus, these methods could be easily implemented in many labs and offer a unique research opportunity to increase our understanding of the role of adult neurogenesis in humans.

### Cerebral blood volume measurements

Cerebral blood volume (CBV) can be measured by several methods, one of which is MRI. In MR-based CBV measurements, the contrast agent gadolinium is injected systemically. The chelated gadolinium used is a non-toxic highly lipophobic agent, thus restricted to the intravascular space when the BBB is not challenged (Zaharchuk, [@B171]). Due to its paramagnetic properties, it creates variations in the local magnetic field which lead to decreased T1 signal intensity. These changes can be used to generate maps of the CBV and cerebral blood flow (CBF) by an array of computational methods (reviewed in Zaharchuk, [@B171]). Among these, the steady-state T1 method is based on the assumption that the MRI signal derives from two separate compartments -- intravascular (vessels) and extravascular (brain parenchyma; Lin et al., [@B84]). When gadolinium is administered, only the T1 signal from the intravascular compartment will decrease, assuming the BBB is intact. Then, the difference between pre-contrast and post-contrast images normalized over a voxel that contains only blood, such as the sagittal sinus, is used to generate the CBV map (Lin et al., [@B84]). The main advantage of the steady-state T1 method, compared to other methods such as bolus tracking (also called dynamic imaging), is that it renders absolute estimations of the CBV, supporting longitudinal studies of brain perfusion, and has high spatial resolution. This method has been validated through correlation with estimations of gray matter CBV using other imaging modalities. However, it requires longer acquisition time and has lower signal-to-noise ratio than bolus tracking (Lin et al., [@B84]). Nevertheless, the steady-state T1 method is well-established for determining CBV (Zaharchuk, [@B171]) and has been recently used by the group of Scott Small to indirectly assess changes in adult human neurogenesis (Pereira et al., [@B119]).

The basis for the CBV studies of neurogenesis is the correlation between angiogenesis and neurogenesis. Increased cortical CBV correlates with angiogenesis in ischemia (Lin et al., [@B83]; Seevinck et al., [@B137]) and gliomas (Aronen et al., [@B4]; Cha et al., [@B15]). In turn, angiogenesis occurs in the hippocampal neurogenic niche (Palmer et al., [@B113]), and both angiogenesis and neurogenesis are elevated in the hippocampus following physical exercise (van Praag et al., [@B155]; Van der Borght et al., [@B154]). Thus, because of the correlation of CBV--angiogenesis and angiogenesis--neurogenesis, the CBV might provide an indirect measure of neurogenesis in the adult human hippocampus (Pereira et al., [@B119]). In fact, the CBV increased selectively in the human dentate gyrus (DG, where NPCs reside) after a 12-week exercise paradigm, and this increase correlated with cognitive performance, such as declarative memory but not delayed recognition (Pereira et al., [@B119]). As a validation experiment, the authors showed that in running mice, the CBV increased in the DG and not in other hippocampal areas, and this increase correlated with the number of 1- to 3-week-old BrdU+ cells (Pereira et al., [@B119]). More recently, others have demonstrated increased number of micro-vessels occurring in parallel to increased proliferation (Ki67+ cells) and the number of newborn cells committed to the neuronal lineage (DCX+ cells) after 10 days of running (Van der Borght et al., [@B154]). However, it remains to be elucidated if the angiogenesis--neurogenesis coupling occurs in conditions other than exercise, which would render the CBV measurements for assessments of human neurogenesis more widely applicable.

### Spectroscopic biomarker of NPCs

Here, the MRI modality used is proton magnetic resonance spectroscopy (^1^H-MRS), which exploits the magnetic properties of different protons to detect an array of small metabolites in the living tissue. Some protons of some metabolites are mobile in the magnetic field, and the relaxation of their spins can be detected by MR. This relaxation is observed as a sinusoid wave of decay in the time domain (free-induction decay, or FID), which is conventionally transformed into a function in the frequency domain (Fourier-fast transform, or FFT; Maletic-Savatic et al., [@B95]). The FFT is usually plotted as a graph of peaks representing the proton content of different metabolites. The *x*-axis represents the resonant frequency of each particular metabolite (in parts per million or ppm); and the *y*-axis represents the intensity of the signal, so that the integrated area under each peak is a readout of the amount of protons that contribute to that particular signal (Sibtain et al., [@B142]). Using this conventional signal analysis, a few relevant metabolites can be detected (Soares and Law, [@B144]): *N*-*acetylaspartate* (NAA), a marker of neurons whose major peak resonates at 2.02 ppm; *Creatine*, resonating at 3.02 ppm, an energy metabolite considered to be stable and thus used as a house-keeping metabolite for normalization; and *Myoinositol*, a marker of astrocytes which resonates at 3.56 ppm. Other metabolites commonly analyzed include choline, alanine, lactate, glutamate, glutamine, glucose, and some macromolecular proteins and lipids (Soares and Law, [@B144]). Using the ^1^H-MRS, our group recently identified a metabolite with main resonance at 1.28 ppm, which was enriched in rodent NPCs and was used to indirectly quantify adult human neurogenesis (Manganas et al., [@B96]).

This metabolite was initially discovered in rodent NPCs, grown as embryonically derived neurospheres, by high-field nuclear magnetic resonance (NMR; Manganas et al., [@B96]; Ma et al., [@B92]), although it had not been previously found in NPCs differentiated in culture from embryonic stem cells (ESCs; Jansen et al., [@B58]). Its association with neurogenesis *in vivo* was validated by microMR spectroscopy, which detected it in the rodent hippocampus, as well as in the cortex after NPC transplantation (Manganas et al., [@B96]). Furthermore, the amount of the metabolite detected by microMR spectroscopy correlated with the number of BrdU+ cells in the hippocampus following an electroconvulsive shock-induced increase in endogenous neurogenesis. These studies further led to imaging of the human hippocampus, where this metabolite was expressed in very small amounts and was not detectable using conventional signal processing. Thus, to extract it from the human ^1^H-MRS, Manganas et al. ([@B96]) utilized singular value decomposition (SVD), a parametric method which models metabolite signals as decaying complex sinusoids in the time domain. The validity and reliability of SVD to quantify the 1.28 ppm signal encountered criticisms mostly due to potential overfitting of the data (Friedman, [@B41]; Hoch et al., [@B54]; Jansen et al., [@B57]; Dong et al., [@B33]). However, most of these issues were addressed using simulated and semi-simulated data showing that the rate of false positives was less than 5% for the range of signal-to-noise ratios found in the initial studies (under −20 dB), and thus that the estimations of human NPCs based on the 1.28 ppm peak were reliable (Djuric et al., [@B30]). Overall, these issues have been considered a matter of optimization of the technique rather than a fundamental problem in the methodology (Romer et al., [@B130]; Dong et al., [@B33]), with the agreement that more research is necessary to unequivocally establish the 1.28 ppm spectral peak as a marker of neurogenesis with clinical value (Djuric et al., [@B30]; Romer et al., [@B130]; Dong et al., [@B33]).

The identity of the 1.28 ppm metabolite remains unknown. Although it most likely contains a lipid component (Manganas et al., [@B96]), its exact molecular nature has not yet been determined and its functional significance for neurogenesis awaits further studies. Recent reports indicate that the 1.28 ppm and adjacent resonances may also be associated with apoptosis. A similar lipidic peak resonating at 1.30 ppm has been also reported in apoptotic rat gliomas *in vivo* (Liimatainen et al., [@B82]), and more recent studies have found that the 1.28 ppm peak in cultured NPC increased during conditions that favored quiescence and apoptosis (Ramm et al., [@B125]). Apoptosis is common in the hippocampal neurogenic niche, as vast amounts of newborn cells die (Sierra et al., [@B143]). Thus, whether the 1.28 ppm peak detected in living brains originates from living or apoptotic NPCs remains to be determined.

Sites of Neurogenesis in the Adult Human Brain
==============================================

Nowadays, the consensus is that adult neurogenesis occurs in two main areas of the brain: the subgranular zone (SGZ) of the DG of the hippocampus, where new granule neurons are locally produced and have been associated with learning and memory, and mood disorders; and the subventricular zone (SVZ), from where newborn cells migrate through the rostral migratory stream (RMS) and give rise to neurons in the OB, related to olfaction (Ma et al., [@B91]). Additionally, there are recent reports of adult neurogenesis in the neocortex, as well as the striatum, amygdala, substantia nigra (SN), and a few other areas in the rodent brain, as reviewed by Gould ([@B48]). In humans, multipotent progenitors have been isolated from the temporal and frontal cortex, as well as the amygdala from patients undergoing brain resection due to epilepsy, trauma, or dysplasia (Arsenijevic et al., [@B5]). However, studies in healthy humans have suggested that neocortical neurogenesis is restricted to the perinatal period or, at least, that the contribution of adult-born neurons to the total cortical population is extremely small and undetectable by ^14^C methods (Spalding et al., [@B146]; Bhardwaj et al., [@B10]).

Neurogenesis in the adult human hippocampus
-------------------------------------------

In rodents, the hippocampal neurogenic cascade starts with the quiescent neuroprogenitors (QNPs; type-1 cells; radial glia), which reside in the SGZ. QNPs proliferate, giving rise to a transient population, the amplifying neuroprogenitors (ANPs; type-2a cells) which in turn proliferate and differentiate into neuronal-committed NBs (type-2b and type-3 cells). Finally, at the end of a 4-week period, the surviving NBs become mature neurons integrated into the circuitry (reviewed by Kempermann et al., [@B70]; Encinas and Enikolopov, [@B38]).

In humans, adult hippocampal neurogenesis was demonstrated by analysis of postmortem tissue of cancer patients (Eriksson et al., [@B39]), and changes in it under different conditions such as physical exercise and aging have been observed indirectly using CBV (Pereira et al., [@B119]) and ^1^H-MRS (Manganas et al., [@B96]) in healthy adults *in vivo*. The presence of functional NPCs in the adult human hippocampus was further demonstrated by culture, expansion, and differentiation of human NPCs *in vitro* (Kukekov et al., [@B76]; Roy et al., [@B131]; Moe et al., [@B107]). A recent study has shown that the adult human SGZ contains DCX-expressing cells that co-localize both with markers of proliferation (MCM2, Ki67, PCNA) and mature neurons (NeuN, β-III-tubulin), supporting the existence of NBs throughout the human lifespan (Knoth et al., [@B72]).

Other studies, however, failed to detect NPCs or proliferating cells in the adult hippocampus of epileptic patients using immunohistochemical methods, such as expression of nestin, vimentin, or Ki67 (Arnold and Trojanowski, [@B3]; Del Bigio, [@B25]; Blumcke et al., [@B11]; Seress et al., [@B138]; Fahrner et al., [@B40]). This conflicting literature can be explained by different sensitivities of the particular method used in each study. Overall, future work is needed to determine all components of the hippocampal neurogenic niche and the cellular types that comprise human neurogenic cascade.

Neurogenesis in the adult SVZ
-----------------------------

In rodents, the stem cells of the SVZ are specialized astrocytes called B cells. These cells proliferate and give rise to C cells, the transient amplifying population of the system (Doetsch et al., [@B31]). These C cells generate NBs or A cells, which form chains of proliferating cells that migrate ensheathed by astrocytes forming the RMS toward the OB, where they differentiate into granule cells and periglomerular interneurons (Lois et al., [@B88]). In non-human primates, the structure is notably similar, with astrocytic-like precursors in the SVZ that generate chains and honeycomb-like structures of migrating NBs that reach the OB through the RMS (Kornack and Rakic, [@B75]; Pencea et al., [@B118]).

In humans, proliferating BrdU+ cells were found in the SVZ, but they did not co-localize with either GFAP or NeuN (Eriksson et al., [@B39]). Similarly to human SGZ NPCs, the functional NPCs from the human SVZ were grown *in vitro* (Kukekov et al., [@B76]) and, more recently, isolated from the healthy and diseased elderly SVZ (Leonard et al., [@B81]). Further studies showed the presence of proliferating putative NPCs, labeled with nestin and PCNA (Bernier et al., [@B9]), as well as putative NBs, labeled with PSA-NCAM, in the human SVZ (Weickert et al., [@B163]). However, only recently was the human SVZ niche thoroughly described. First, a well-defined astrocytic ribbon formed by the B cells was observed in the SVZ, similarly to rodent SVZ, but no evidence of cells migrating in an organized RMS was found (Sanai et al., [@B134]). The human RMS remained elusive, until a report that it was organized around the lateral ventricular extension which reached the OB (Curtis et al., [@B20]). This report was criticized by Alvarez-Buylla and colleagues, who claimed that it had not unquestionably proved the existence of an olfactory ventricle and the migrating, proliferating NBs in the RMS (Sanai et al., [@B133]). Further study then showed scarce cells that co-expressed markers of proliferation (PCNA) and NBs (PSA-NCAM), but no clear evidence of migration (Kam et al., [@B67]). In addition, it appears that the human RMS consists of four layers, similar to the SVZ (Kam et al., [@B67]), which prompted others to suggest that the human RMS may be a rostral extension of the proliferative zone, rather than the migratory pathway as found in rodents and non-human primates (Whitman and Greer, [@B164]). Nonetheless, there is no consensus in the literature on whether the SVZ/RMS are actively providing a source of newborn neurons to the human OB throughout adulthood.

Finally, the human OB hosts NPCs, which have been isolated from patients undergoing neurosurgery and grown in culture, where they differentiated into neurons, astrocytes, and oligodendrocytes (Pagano et al., [@B112]). In agreement, new neurons seem to be produced locally in the human OB, as shown by co-localization with Ki67 and NeuroD (Bedard and Parent, [@B8]). However, the significance of local neurogenesis in the adult human OB is still debatable.

Relevance of Adult Neurogenesis to Human Disease
================================================

The majority of studies on human neurogenesis compare findings in healthy people to those in patients with a variety of neurological diseases. A summary comparing the alteration in neurogenesis in rodent models of disease and human patients is shown in Table [2](#T2){ref-type="table"}. These studies use immunohistochemistry to detect biomarkers of proliferation or specific cell-types, and thus are only able to report differences in proliferation and putative NPCs and NBs (pNPCs, pNBs), but not actual neurogenesis (i.e., formation of new neurons). Thus, we label these detected cells "putative" because none of the studies demonstrated that proliferating cells differentiated into mature, functional neurons. To directly reach the conclusion that neurogenesis is occurring lineage tracing using BrdU or analogs is required.

###### 

**Adult neurogenesis during disease**.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                 Area       Rodent data                                                                           Human data
  ----------------------- ---------- ------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Epilepsy                Hippo.     Acute increase in proliferation                                                       Increase in pNPCs and proliferation in pediatric patients

                                     Acute increase in neurogenesis                                                        Increase or no change in proliferation in adult patients

                                     Aberrant and ectopic new neurons\                                                     Decrease, no changed or increase in pNBs in adult patients
                                     Chronic depletion                                                                     

  Huntington\'s disease   SVZ        Increased or unchanged SVZ proliferation migration of new neurons into the striatum   Increase in proliferation; thicker SVZ increase in pNPCs and pNBs

  Alzheimer\'s disease    SVZ        Decrease in proliferation\                                                            Decrease in proliferation\
                                     Decrease in differentiation                                                           Increase in pNPCs

                          Hippo.     Increase, no change or decrease in proliferation\                                     No change in proliferation\
                                     Increase in neurogenesis\                                                             Increase in pNBs
                                     Decrease in differentiation and survival of newborn neurons                           

  Parkinson\'s disease    SVZ        Decrease in proliferation\                                                            Decrease in proliferation\
                                     Transient decrease in OB neurogenesis\                                                Decrease in putative OB progenitors\
                                     Increase in OB neurogenesis and total neurons                                         Increase in OB neurogenesis and\
                                                                                                                           DA neurons

                          Hippo.     Decrease in proliferation\                                                            Decrease in pNPCs
                                     No proliferation or NPCs                                                              

                          S. nigra   Induction of neurogenesis                                                             No proliferation or pNPCs

  Stroke                  SVZ        Increase in proliferation\                                                            NR
                                     Increase in neurogenesis                                                              

                          Hippo.     Increase in proliferation\                                                            NR
                                     Increase in neurogenesis                                                              

                          Striatum   Induction of neurogenesis from SVZ progenitors                                        NR

                          Cortex     Induction of neurogenesis from SVZ progenitors                                        Increase in proliferation\
                                                                                                                           Increase in pNBs

  Depression              Hippo.     Antidepressants increase proliferation and neurogenesis                               Increase or no changes in proliferation

                                                                                                                           Increase in pNPCs in patients treated with antidepressants
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*This table summarizes the major changes in neurogenesis in human neurological and psychiatric disorders. For details and references, see main text*.

*Hippo., hippocampus; S. nigra, substantia nigra; NR, non-reported*.

Epilepsy
--------

Epilepsy is a common human disease that affects more than 50 million people worldwide (Kuruba et al., [@B77]). One of the most intractable forms is temporal lobe epilepsy (TLE), characterized by altered electrical activity, aberrant synaptic reorganization and neurodegeneration in the hippocampus, as well as development of depression and impairments in learning and memory (Kuruba et al., [@B77]).

In rodents, there is abundant literature reporting that hippocampal neurogenesis increases in models of acute seizures, either by administration of glutamate receptors agonists such as kainic acid, or by electrical stimulation of the hippocampus or the piriform cortex. In these models an increment in the proliferation of the hippocampal NPCs results in a concomitant increase in the number of newborn neurons (reviewed by Parent, [@B115]; Curtis et al., [@B19]; Kuruba et al., [@B77]). However, the newborn neurons are located ectopically (in the hilus and the molecular layer of the dentate gyrus) and display aberrant connectivity and morphology (Parent et al., [@B117]; Scharfman et al., [@B136]). The seizure-induced abnormal neurogenesis may have detrimental consequences and contribute to aberrant synaptic reorganization (Parent, [@B115]). In contrast, in models of chronic epilepsy, neurogenesis seems to return to basal levels or even to be downregulated as compared to control animals (Kuruba et al., [@B77]).

Several studies have reported changes in adult neurogenesis in patients with TLE, who were all pharmacoresistant and had to undergo temporal lobectomy, providing the source for studies of neurogenesis. Utilizing Ki67 labeling the initial study showed no evidence of proliferation in the adult epileptic SGZ, since the number of Ki67+ cells was not significantly larger compared to other DG regions (Del Bigio, [@B25]). In addition, the number of pNBs (PSA-NCAM+ cells) was smaller in TLE patients than in age-matched controls (Mikkonen et al., [@B101]). Further comparison of adult TLE patients and controls showed similar levels of proliferation, measured by the number of Ki67+ and MCM2+ cells, as well as DCX protein expression and the number of DCX+ cells (Fahrner et al., [@B40]). In contrast, pediatric (\<19 months of age) TLE patients had increased number of proliferating pNPCs, labeled with nestin and Ki67 (Blumcke et al., [@B11]). More recent studies, however, contradict the previous literature. One study described a not quantified increase in proliferating cells (PCNA+ cells), and pNPCs (vimentin, musashi+ cells) in the SGZ and SVZ of adult TLE patients compared to controls (Crespel et al., [@B18]), while another reported augmented DCX protein and gene expression and number of pNBs (DCX+ cells) in TLE patients in the hippocampus and other temporal cortical regions (Liu et al., [@B85]). In these patients the DCX+ cells expressed markers of the neuronal lineage, such as PSA-NCAM or NeuN, but the authors did not provide the rationale for their findings contradicting previous literature and only noted that the effect of TLE on human neurogenesis was not as "dramatic" as in animal models of epilepsy (Liu et al., [@B85]). Finally, although many *ex vivo* studies showed the presence of functional NPCs in the epileptic hippocampus (Kukekov et al., [@B76]; Roy et al., [@B131]; Moe et al., [@B107]), it has been recently shown that their proliferative and multipotential properties *in vitro* depend on disease duration and were almost absent in epileptic patients with mesial temporal sclerosis, a late consequence of TLE (Paradisi et al., [@B114]). In conclusion, in infants, epilepsy is associated with increased proliferation in the hippocampus, but whether this proliferation leads to an increase of newborn neurons remains unknown. In adults, reports are controversial and most likely reflect a wide range of disease duration, which apparently affects NPCs (Paradisi et al., [@B114]). Whether changes in neurogenesis also relate to the changes in mood and cognitive performance observed in TLE patients remains to be determined.

Epilepsy also alters SVZ neurogenesis. In rats, pilocarpin-induced status epilepticus produced an increased proliferation of SVZ NPCs as well as an expansion of the RMS, which contained more proliferating cells and NBs (Parent et al., [@B116]). In addition, some cells in the RMS were found to migrate ectopically into the surrounding cortical parenchyma, although the majority of these ectopic cells did not survive (Parent et al., [@B115]). In human, increased proliferation, ectopic parenchymal migration, and neuronal differentiation were also found using organotypic slice preparations from tissue resected from patients with a variety of intractable cortical seizures (Gonzalez-Martinez et al., [@B47]). The functional significance of increased neurogenesis and ectopic migration of SVZ precursors induced by SE in rodents and humans remains to be established.

Huntington\'s disease
---------------------

Huntington\'s disease (HD) is caused by expanded CAG repeats in the huntingtin gene, which leads to protein accumulation and neurodegeneration in the striatum, a brain area that lies below the SVZ. In transgenic mice models of HD, in which little striatal neurodegeneration occurs, neurogenesis in the SVZ remains unaltered; whereas in rat models of striatal degeneration an increased SVZ proliferation is observed (reviewed by Curtis et al., [@B19]). Interestingly, some of the newly generated cells are able to migrate into the damaged striatum, where they express neuronal markers (Tattersfield et al., [@B153]), although it is unknown whether they are functionally mature neurons. These results suggested an endogenous regeneration potential in HD because the new born neurons would take long time to develop huntingtin inclusions and in the meanwhile could contribute to maintaining the striatal circuitry (Curtis et al., [@B19]).

Studies of HD patients have shown increased intensity of PCNA staining in the SVZ lining of the striatum compared to age-matched controls, suggesting an increase in SVZ proliferation. Additionally, the expression levels of PCNA correlated with the number of CAG repeats in these patients. The proliferating cells expressed markers of glia (GFAP) and neurons (β-III-Tubulin), suggesting the presence of putative B and A cells, respectively (Curtis et al., [@B21]). Further, the SVZ was thicker due to an increase in the number of B cells, identified by cellular morphology, and the number of dividing cells, labeled with PCNA, in HD patients compared to age-matched controls (Curtis et al., [@B22],[@B23]). Unexpectedly, some of the proliferating PCNA+ cells expressed markers of mature neurons such as βIII-Tubulin and this was interpreted as increased neurogenesis in HD patients (Curtis et al., [@B22]). However, it takes days, if not weeks, for newborn cells to express markers of mature neurons. Therefore, an aberrant expression of PCNA in mature neurons or an aberrant expression of βIII-Tubulin in dividing cells in the SVZ of HD patients cannot be ruled out. Finally, migration of the newborn cells from the SVZ into the damaged human striatum and their neuronal differentiation has not been described yet and, thus, it remains unknown if the endogenous SVZ cells can be harnessed for repair in HD patients.

Alzheimer\'s disease
--------------------

Alzheimer\'s disease (AD) is characterized by accumulation of β-amyloid and neurofibrillary tangles containing hyperphosphorylated tau protein throughout the cortex and the hippocampus, resulting in progressive dementia (Curtis et al., [@B19]). Some pathological features of AD can be modeled in transgenic mice overexpressing amyloid precursor protein and presenilin 1 (APP/PS1). In these mice, memory impairment and increased hippocampal proliferation and neurogenesis were observed at 9, but not 3 months of age (Yu et al., [@B170]). However, earlier works showed that 6-month-old APP/PSE1 mice have unaltered proliferation and short-term survival (1--13 days), whereas they have a significant reduction of long-term survival (30--42 days) and differentiation (Verret et al., [@B157]). In addition, other transgenic mouse models of AD have shown otherwise. For instance, in triple transgenic mice (APP/PSE1/Tau) there is a gradual decrease in SGZ proliferation starting at 6 months of age (Rodriguez et al., [@B128]). On the other hand, 3-month-old mice expressing mutated APP have increased proliferation (Jin et al., [@B59]) although this increase was reverted to control levels in older animals (Lopez-Toledano and Shelanski, [@B89]). Finally, in 6-week-old transgenic mouse expressing human APP showed decreased proliferation in control housing conditions as well as a decreased 4-week survival in enriched environment conditions (Naumann et al., [@B111]). In postmortem hippocampal samples from patients with advanced AD, an increased expression of NB proteins (DCX, PSA-NCAM, and NeuroD) compared to age-matched controls was reported, suggesting increased neurogenesis perhaps as a compensatory mechanism to cope with the AD-related cognitive impairment (Jin et al., [@B60]). However, a more recent study of presenile AD patients failed to demonstrate increased proliferation in the DG, whereas it showed an increased proliferation (Ki67+ cells) associated with gliogenesis and angiogenesis in other hippocampal regions. Further, the same study attributed changes in DCX immunolabeling to postmortem breakdown (Boekhoorn et al., [@B12]). Thus, it is clear that more comprehensive studies are needed to clarify the changes in SGZ neurogenesis in AD. Furthermore, the relation between potentially altered neurogenesis and the cognitive impairments observed in AD remains to be elucidated (Lazarov et al., [@B78]).

Subventricular zone neurogenesis is also altered in mouse AD-models. For instance, transgenic APP or PSE1 mice as well as wild-type mice infused in the lateral ventricles with βA peptide had reduced SVZ proliferation compared to control mice (Haughey et al., [@B52]; Rodriguez et al., [@B129]; Veeraraghavalu et al., [@B156]). Decreased proliferation and neuronal differentiation were also observed in cultured NPCs isolated from PSE1 mutant SVZ (Veeraraghavalu et al., [@B156]) and from APP/PS1 mutant SVZ (Demars et al., [@B26]). In human AD patients, decreased proliferation (Ki67+ cells) accompanied by a puzzling increase in nestin expression was observed in postmortem sections (Ziabreva et al., [@B175]). In agreement, cultured embryonic human NPC had decreased proliferation and increased apoptosis when treated with Aβ peptide compared to control NPCs treated with vehicle (Haughey et al., [@B52]). Thus, there are consistently lower levels in SVZ neurogenesis in AD patients as well as in and rodent AD models, prompting the suggestion that impaired SVZ neurogenesis may have functional consequences in AD (Curtis et al., [@B19]). For instance, olfactory deficits significantly predict development of AD in patients with mild cognitive impairment (Devanand et al., [@B28]), although whether these olfactory deficits are related to decreased SVZ neurogenesis remains unknown.

Parkinson\'s disease
--------------------

The major hallmark of the Parkinson\'s disease (PD) is the death of dopaminergic neurons in the SN, with consequent impairment of movement control, mood, and motivation (Hoglinger et al., [@B55]). In animal models of PD, a reduced proliferation in the SVZ overlaying the striatum is observed. C and A cells in the SVZ receive dopaminergic fibers from the SN (Hoglinger et al., [@B55]). In rodents, this dopaminergic innervation controls the proliferation of these two cell types, because the injection of a toxic dopamine analog (6-hydroxydopamine) in the nigrostriatal pathway dennervates both the striatum and the SVZ and results in decreased SVZ proliferation (Hoglinger et al., [@B55]), resulting in a transient decrease of newborn neurons in the OB granule cell layer (Hoglinger et al., [@B55]; Winner et al., [@B165]). In the lesioned mice, administration of a dopaminergic precursor (levodopa) partially recovered SVZ proliferation close to control levels (Hoglinger et al., [@B55]). Similar results were obtained in PD patients. The number of SVZ proliferating cells, labeled with PCNA, as well as OB pNPCs (nestin+ cells) was reduced compared to age-matched controls (Hoglinger et al., [@B55]), although no changes in the number of cells in the OB granule cell layer have been reported.

Interestingly, in the OB glomerule cell layer there is an increase in the number of newborn as well as total dopaminergic cells, expressing the synthesizing enzyme tyrosine hydroxylase, both in rodents whose nigrostriatal pathway was lesioned with 6-hydroxydopamine (Winner et al., [@B165]) and in PD patients (Huisman et al., [@B56]). This increase in dopaminergic cells remains unexplained and it is unexpected in the light of the decreased SVZ proliferation. Nonetheless, because dopamine inhibits olfactory transmission, it has been suggested that the increase in OB dopaminergic neurons could explain the hyposmia (Huisman et al., [@B56]) that occurs in up to 95% of PD patients prior to the onset of other clinical symptoms (Haehner et al., [@B50]). Dopaminergic innervation may also regulate neurogenesis in the hippocampus. In rodents, lesions of the nigrostriatal pathway decrease hippocampal proliferation (Hoglinger et al., [@B55]; Suzuki et al., [@B150]), and in the hippocampus of PD patients, less pNPCs (nestin+ cells) are observed compared to age-matched controls (Hoglinger et al., [@B55]). While initial reports suggested the neurogenesis was induced in the SN in rodent models of PD (Zhao et al., [@B174]), later studies, however, showed no evidences of proliferation or NPCs in the SN either in rodent models of PD (Frielingsdorf et al., [@B42]; Yoshimi et al., [@B168]) nor in PD patients (Yoshimi et al., [@B168]).

Stroke/ischemia
---------------

A stroke, or cerebrovascular accident, results from occlusion of cerebral arteries leading to decreased local blood flow (ischemia) or from a hemorrhage. In the stroked tissue, two areas of injury can be discriminated: the core infarcted area, where neurons die of necrosis and very little, if any, regeneration is possible; and the penumbra area, which surrounds the infarcted area, is perfused by collateral arteries, and is not irreversibly damaged. Given that the ischemic stroke is the third most frequent cause of mortality in industrialized countries, major scientific efforts have been directed toward discoveries of therapies to facilitate recovery from the insult.

In rodent and non-human primate models of stroke, such as occlusion of the medial cerebral artery occlusion (MCAO), adult neurogenesis is up-regulated both in the SVZ--RMS--OB and the hippocampus (Jin et al., [@B61]; Zhang et al., [@B172]; Koketsu et al., [@B73]; Lledo et al., [@B86]). In addition, stroke also induces ectopic neurogenesis in penumbra areas, such as the striatum, due to atypical migration of SVZ newborn cells (Arvidsson et al., [@B6]). Cortical neurogenesis in the penumbra area in rodent models of stroke has been found by some (Gu et al., [@B49]; Jin et al., [@B62]) but not by others (Arvidsson et al., [@B6]). Interestingly, the newborn cells differentiated into striatal neurons and acquired the same phenotype of the neurons which had died as a consequence of the stroke, suggesting that neuronal replacement can occur in the stroked striatum (Arvidsson et al., [@B6]). Although the vast majority of the striatal newborn cells died, possibly due to an unfavorable environment (Arvidsson et al., [@B6]), stroke-induced striatal neurogenesis seems to have functional consequences in rodents, since it has been shown that the transgenic ablation of the NB protein DCX prevented stroke-induced neurogenesis and worsened the sensorimotor and behavioral deficits after MCAO (Jin et al., [@B63]).

This research indicated that harnessing aberrant striatal neurogenesis in stroke may be useful to reduce the neurological deficits in patients (reviewed in Zhang and Chopp, [@B173]). The patients who suffered the ischemic, middle cerebral artery stroke showed increased proliferation of putative B cells (Ki67, GFAP+ cells) and putative C cells (PSA-NCAM+ cells), in the ipsilateral SVZ compared to the contralateral side of the stroke (Marti-Fabregas et al., [@B98]). In addition, there were traces of ectopic neurogenesis not in the striatum, but in the cortex. A significant increase in proliferating Ki67+ cells and pNBs (PSA-NCAM+ cells) was found in the cortical penumbra region of ischemic stroke patients compared to age-matched controls (Jin et al., [@B64]; Macas et al., [@B93]) as well as in perihematomal regions in patients with intracerebral hemorrhage (Shen et al., [@B141]). The relevance of this increase in cortical neurogenesis in stroke patients remains to be investigated, but the phenomena certainly raise the hope that neurogenesis might be harnessed as a possible treatment for stroke patients.

Mood disorders
--------------

Depression, or major depressive disorder (MDD), is characterized by anhedonia and the absence of positive affect (Craske et al., [@B17]). MDD is thought to be caused by an imbalance in the levels of monoamines, such as serotonin and noradrenalin, as formulated in the "monoamine hypothesis of depression" (Duman et al., [@B36]; Wong and Licinio, [@B166]). This hypothesis is strongly supported by the ability of antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), to improve the symptomatology by increasing synaptic levels of monoamines (Wong and Licinio, [@B166]). However, while antidepressant drugs modify monoamine levels within hours, it takes weeks of daily treatments to observe the behavioral effects, indicating that long-term changes underlie the effects of antidepressant therapies (Wong and Licinio, [@B166]). Structural changes in the cortex and hippocampus, such as alterations in neuronal morphology, synaptic plasticity, and cell survival, may also be part of the disease (Duman et al., [@B36]). For instance, MDD patients may have hippocampal atrophy (Sheline et al., [@B140]), which correlates with poor cognitive performance in these patients (Frodl et al., [@B43]). In addition, MDD patients have decreased pyramidal neuronal soma size and higher density of glial, pyramidal, and granule cells in the hippocampus compared to age-matched controls (Stockmeier et al., [@B148]). Together, these results suggest a significant reduction in the neuropil (glial and neuronal processes) in MDD patients (Stockmeier et al., [@B148]). While the absolute numbers of glia and neurons in the hippocampus of MDD patients are unknown (Stockmeier et al., [@B148]), small increases in hippocampal apoptosis in MDD patients have been reported (Lucassen et al., [@B90]).

The hippocampal pathology in MDD has led to the "neurogenesis hypothesis of depression." Postulated by Drew and Hen ([@B34]), the hypothesis states that altered levels of adult hippocampal neurogenesis may underlie the pathology of depression as well as the behavioral effects of antidepressants. This hypothesis is based on several lines of evidence showing that in rodents, chronic antidepressant treatments increase hippocampal neurogenesis (Malberg et al., [@B94]) and that, conversely, hippocampal neurogenesis is necessary for the behavioral effects of antidepressant drugs (Santarelli et al., [@B135]). The main caveat of this hypothesis is that neurogenesis seems not to be sufficient to cause depression, because decreased neurogenesis does not always induce depressive behaviors, and vice versa, depressive behaviors can be induced in experimental paradigms that do not affect neurogenesis (Vollmayr et al., [@B159]). To further complicate the interpretation of the data, the depression-induced morphological alterations, including those in neurogenesis, have generally been blamed on depression-related stress (Duman et al., [@B36]).

Stress, or more properly, the failure to adapt to stressful situations, is a shared symptom of depression and other mood disorders, such as anxiety and fear disorders (Craske et al., [@B17]), although is still under debate whether it is a concurrent epiphenomenon or an actual pathological state (Wong and Licinio, [@B166]). The connection of stress, anxiety, and MDD is not trivial, because the most commonly utilized rodent models of depression, such as learned helplessness, chronic mild stress, and chronic psychosocial stress induce depressive behaviors by increasing stress levels (Vollmayr et al., [@B159]; Pryce and Seifritz, [@B120]). Stress, through the actions of glucocorticoids, reduces adult hippocampal neurogenesis (Mirescu and Gould, [@B104]), produces dendritic atrophy (McEwen, [@B100]), and leads to decreased hippocampal volume (Tata and Anderson, [@B152]). From the rodent literature, it is therefore difficult to extract a clear picture of whether the alterations in adult hippocampal neurogenesis are due to stress, anxiety, depression, or a combination of these factors.

In MDD patients, recent studies have shown alterations in adult hippocampal neurogenesis (Reif et al., [@B126]; Boldrini et al., [@B13]). An initial study on postmortem samples of a cohort of 15 MDD patients showed no alterations in proliferation (Ki67+ cells) compared to age-matched controls (Reif et al., [@B126]). In contrast, a more recent study of a cohort of 19 MDD patients treated with TCAs such as nortriptyline, showed a significant increase in proliferation (Ki67+ cells) compared to the untreated MDD patients. In addition, a significant increase in the number of pNPCs (nestin+ cells) was found in patients treated with TCAs or SSRIs such as fluoxetine, compared to the untreated MDD patients (Boldrini et al., [@B13]). Interestingly, and similar to the observation that decreased neurogenesis is not required to induce depression-like behavior in rodents (Vollmayr et al., [@B159]), there were no significant differences in the number of proliferative cells or pNPCs in MDD patients compared to age-matched controls (Boldrini et al., [@B13]). Several limitations where identified, such as the small sample size, the possibility that treated MDD patients had more severe symptoms than untreated patients (hence, the prescription of pharmacological treatment), and the high incidence of suicide in the untreated patients (Boldrini et al., [@B13]). Taken together, these data suggest that decreased neurogenesis is not causative for depressive symptoms; however, treatment with antidepressants does improve the symptoms while increasing neurogenesis in the adult hippocampus. Further research needs to test the correlations between neurogenesis, MDD, stress, and antidepressant drugs. In particular, methods to assess human neurogenesis *in vivo* are of particular importance for longitudinal studies in MDD patients, to quantify neurogenesis before and after the antidepressant treatment, and in correlation with the onset and/or improvement of depressive symptoms.

Miscellanea
-----------

Finally, there is also sporadic evidence that adult neurogenesis may be altered in other brain diseases. For instance, in *traumatic brain injury*, increased hippocampal proliferation has been reported in humans (Gerber et al., [@B44]) and mice (Yu et al., [@B169]). In patients with *hypoxic-ischemic encephalopathy*, which results in neuronal loss in the cortex and the hippocampus, there is a non-significant increase in PCNA labeled cells (Mattiesen et al., [@B99]). During *bacterial meningitis* an increase in hippocampal proliferation as well as the number of pNBs was observed (Gerber et al., [@B44]), although in mice inflammation results in decreased proliferation and neurogenesis (Monje et al., [@B108]). In patients with *subarachnoid hemorrhage*, increased mRNA and protein levels of vimentin, musashi, and nestin were observed in the frontal lobe compared to control brains, while proliferating pNPCs (Ki67, nestin+ cells) were also found in the damaged frontal lobes (Sgubin et al., [@B139]). In *autism*, it has recently been suggested that neurogenesis may be altered because of the found increased thickness and dysplasia of the SVZ (Wegiel et al., [@B162]). In *schizophrenia*, decreased hippocampal proliferation (Ki67+ cells) has been reported (Reif et al., [@B126]), in agreement with the findings of decreased NPC proliferation (Mao et al., [@B97]) and aberrant morphology and excitability of the newborn neurons in mice with lower expression of disrupted-in-schizophrenia 1 (DISC1), a schizophrenia susceptibility gene (Duan et al., [@B35]). In *alcohol abuse* patients, no significant differences in hippocampal proliferation have been found (Reif et al., [@B126]), although chronic alcohol exposure decreases neurogenesis in rats (He et al., [@B53]).

Conclusion
==========

Overall, studies of adult human neurogenesis, even though hampered by limitations of the available methodologies for both *ex vivo* and *in vivo* assessments, are promising. Development of new antibodies targeted to human antigens will certainly improve immunohistochemical data, but even then, such labeling will provide only putative information. It is in combination with BrdU labeling that the production of new neurons can be assessed and quantified. As more BrdU labeled tissue is generated, the changes in the neurogenic cascade that accompany brain disorders will be elucidated. However, several considerations need to be taken into account when studying postmortem human tissue, in particular the postmortem delay, the cause of death, and the age at the time of death. Thus, the future of adult human neurogenesis research and the prospects of harnessing its potential for treatments of brain disorders will heavily depend on the development and thorough validation of methods for *in vivo* assessments, as those offer unique opportunity for both cross-sectional and longitudinal studies of the neurogenic niches while they are intact within the living brain tissue.
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